Plaque Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major plaque psoriasis markets are expected to exhibit a CAGR of 8.93% during 2024-2034.
The plaque psoriasis market has been comprehensively analyzed in IMARC's new report titled "Plaque Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Plaque psoriasis is a chronic autoimmune disease characterized by the formation of raised, red, scaly skin patches known as plaques. These plaques can vary in size and location but are typically found on the elbows, knees, scalp, and lower back. They can be itchy, painful, uncomfortable, and even bleed in severe cases. Various other symptoms may include dry and cracked skin, joint pain or stiffness, nail changes like pitting or separation from the nail bed, etc. In addition to the physical indications, the ailment can significantly impact a person's mental health and quality of life, causing embarrassment, social isolation, and depression. The diagnosis of plaque psoriasis involves a physical examination of the affected skin, including an assessment of the size, shape, and location of the plaques. A doctor may also ask about family history, medical history, and any other symptoms the patient may be experiencing. In some cases, a skin biopsy is necessary to confirm the diagnosis. Numerous other procedures, such as blood tests, joint X-rays, or a skin scraping to check for fungal infection, may be recommended if there are concerns about related conditions or further possible causes of symptoms.
The increasing cases of immune system dysfunction in which the immune system mistakenly attacks healthy skin cells, leading to inflammation and the formation of plaques, are primarily driving the plaque psoriasis market. Moreover, the escalating utilization of Vitamin D analogs, such as calcipotriene and calcitriol, for reducing the severity of disease symptoms, including scaling, redness, itching, etc., and decreasing the thickness of plaques is further augmenting the market growth. Besides this, the widespread adoption of phototherapy as a treatment option since it is well-tolerated, helps to prevent flare-ups, and improves skin texture is also creating a positive outlook for the market. Furthermore, various key players are making extensive investments in developing novel therapies to manage cytokines and other immune system proteins that promote skin inflammation and the formation of psoriatic plaques. This, in turn, is acting as another significant growth-inducing factor. Additionally, the inflating demand for biologics, which target specific proteins in the immune system to reduce inflammation, for treating moderate to severe psoriasis that has not responded to other treatments, is expected to drive the plaque psoriasis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the plaque psoriasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for plaque psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plaque psoriasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plaque psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plaque psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current plaque psoriasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the plaque psoriasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the plaque psoriasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the plaque psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of plaque psoriasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of plaque psoriasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of plaque psoriasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with plaque psoriasis across the seven major markets?
What is the size of the plaque psoriasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of plaque psoriasis?
What will be the growth rate of patients across the seven major markets?
Plaque Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for plaque psoriasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plaque psoriasis market?
What are the key regulatory events related to the plaque psoriasis market?
What is the structure of clinical trial landscape by status related to the plaque psoriasis market?
What is the structure of clinical trial landscape by phase related to the plaque psoriasis market?
What is the structure of clinical trial landscape by route of administration related to the plaque psoriasis market?
The plaque psoriasis market has been comprehensively analyzed in IMARC's new report titled "Plaque Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Plaque psoriasis is a chronic autoimmune disease characterized by the formation of raised, red, scaly skin patches known as plaques. These plaques can vary in size and location but are typically found on the elbows, knees, scalp, and lower back. They can be itchy, painful, uncomfortable, and even bleed in severe cases. Various other symptoms may include dry and cracked skin, joint pain or stiffness, nail changes like pitting or separation from the nail bed, etc. In addition to the physical indications, the ailment can significantly impact a person's mental health and quality of life, causing embarrassment, social isolation, and depression. The diagnosis of plaque psoriasis involves a physical examination of the affected skin, including an assessment of the size, shape, and location of the plaques. A doctor may also ask about family history, medical history, and any other symptoms the patient may be experiencing. In some cases, a skin biopsy is necessary to confirm the diagnosis. Numerous other procedures, such as blood tests, joint X-rays, or a skin scraping to check for fungal infection, may be recommended if there are concerns about related conditions or further possible causes of symptoms.
The increasing cases of immune system dysfunction in which the immune system mistakenly attacks healthy skin cells, leading to inflammation and the formation of plaques, are primarily driving the plaque psoriasis market. Moreover, the escalating utilization of Vitamin D analogs, such as calcipotriene and calcitriol, for reducing the severity of disease symptoms, including scaling, redness, itching, etc., and decreasing the thickness of plaques is further augmenting the market growth. Besides this, the widespread adoption of phototherapy as a treatment option since it is well-tolerated, helps to prevent flare-ups, and improves skin texture is also creating a positive outlook for the market. Furthermore, various key players are making extensive investments in developing novel therapies to manage cytokines and other immune system proteins that promote skin inflammation and the formation of psoriatic plaques. This, in turn, is acting as another significant growth-inducing factor. Additionally, the inflating demand for biologics, which target specific proteins in the immune system to reduce inflammation, for treating moderate to severe psoriasis that has not responded to other treatments, is expected to drive the plaque psoriasis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the plaque psoriasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for plaque psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plaque psoriasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plaque psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plaque psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current plaque psoriasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the plaque psoriasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the plaque psoriasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the plaque psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of plaque psoriasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of plaque psoriasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of plaque psoriasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with plaque psoriasis across the seven major markets?
What is the size of the plaque psoriasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of plaque psoriasis?
What will be the growth rate of patients across the seven major markets?
Plaque Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for plaque psoriasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plaque psoriasis market?
What are the key regulatory events related to the plaque psoriasis market?
What is the structure of clinical trial landscape by status related to the plaque psoriasis market?
What is the structure of clinical trial landscape by phase related to the plaque psoriasis market?
What is the structure of clinical trial landscape by route of administration related to the plaque psoriasis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PLAQUE PSORIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PLAQUE PSORIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PLAQUE PSORIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PLAQUE PSORIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PLAQUE PSORIASIS - UNMET NEEDS
10 PLAQUE PSORIASIS - KEY ENDPOINTS OF TREATMENT
11 PLAQUE PSORIASIS - MARKETED PRODUCTS
11.1 List of Plaque Psoriasis Marketed Drugs Across the Top 7 Markets
11.1.1 Duobrii (Tazarotene/ulobetasol) - Ortho Dermatologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Siliq (Brodalumab) - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ilumya (Tildrakizumab) - Almirall/Sun Pharmaceutical Industries
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zoryve (Roflumilast topical) - Arcutis Biotherapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Enbrel (Etanercept) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PLAQUE PSORIASIS - PIPELINE DRUGS
12.1 List of Plaque Psoriasis Pipeline Drugs Across the Top 7 Markets
12.1.1 ABY 035 - Affibody
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AK 101 - Akeso Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ESK001 - Alumis Inc
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TLL018 - Hangzhou Highlightll Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 JNJ 77242113 - Janssen Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PLAQUE PSORIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PLAQUE PSORIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PLAQUE PSORIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Plaque Psoriasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Plaque Psoriasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Plaque Psoriasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Plaque Psoriasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Plaque Psoriasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Plaque Psoriasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Plaque Psoriasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Plaque Psoriasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Plaque Psoriasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Plaque Psoriasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Plaque Psoriasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Plaque Psoriasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Plaque Psoriasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Plaque Psoriasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Plaque Psoriasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Plaque Psoriasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Plaque Psoriasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Plaque Psoriasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Plaque Psoriasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Plaque Psoriasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Plaque Psoriasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Plaque Psoriasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Plaque Psoriasis - Access and Reimbursement Overview
16 PLAQUE PSORIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PLAQUE PSORIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PLAQUE PSORIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PLAQUE PSORIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PLAQUE PSORIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PLAQUE PSORIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PLAQUE PSORIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PLAQUE PSORIASIS - UNMET NEEDS
10 PLAQUE PSORIASIS - KEY ENDPOINTS OF TREATMENT
11 PLAQUE PSORIASIS - MARKETED PRODUCTS
11.1 List of Plaque Psoriasis Marketed Drugs Across the Top 7 Markets
11.1.1 Duobrii (Tazarotene/ulobetasol) - Ortho Dermatologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Siliq (Brodalumab) - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ilumya (Tildrakizumab) - Almirall/Sun Pharmaceutical Industries
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zoryve (Roflumilast topical) - Arcutis Biotherapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Enbrel (Etanercept) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PLAQUE PSORIASIS - PIPELINE DRUGS
12.1 List of Plaque Psoriasis Pipeline Drugs Across the Top 7 Markets
12.1.1 ABY 035 - Affibody
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AK 101 - Akeso Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ESK001 - Alumis Inc
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 TLL018 - Hangzhou Highlightll Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 JNJ 77242113 - Janssen Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PLAQUE PSORIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PLAQUE PSORIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PLAQUE PSORIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Plaque Psoriasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Plaque Psoriasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Plaque Psoriasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Plaque Psoriasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Plaque Psoriasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Plaque Psoriasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Plaque Psoriasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Plaque Psoriasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Plaque Psoriasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Plaque Psoriasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Plaque Psoriasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Plaque Psoriasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Plaque Psoriasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Plaque Psoriasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Plaque Psoriasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Plaque Psoriasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Plaque Psoriasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Plaque Psoriasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Plaque Psoriasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Plaque Psoriasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Plaque Psoriasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Plaque Psoriasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Plaque Psoriasis - Access and Reimbursement Overview
16 PLAQUE PSORIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PLAQUE PSORIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PLAQUE PSORIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
